Table 3.
Most common treatment-related adverse events occurring in at least 5% of patients (Safety set).
| Infigratinib (N = 26) | ||
|---|---|---|
| Adverse event, n (%) | All grades | Grade 3a |
| Total | 22 (84.6) | 7 (26.9) |
| Hyperphosphatemia | 20 (76.9) | 1 (3.8) |
| Fatigue | 7 (26.9) | 1 (3.8) |
| Diarrhea | 5 (19.2) | 0 |
| Hyperlipasemia | 4 (15.4) | 2 (7.7) |
| Stomatitis | 4 (15.4) | 1 (3.8) |
| Dry skin | 4 (15.4) | 0 |
| Hypophosphatemia | 3 (11.5) | 2 (7.7) |
| Alopecia | 3 (11.5) | 0 |
| Decreased appetite | 3 (11.5) | 0 |
| Dyspepsia | 3 (11.5) | 0 |
| Onycholysis | 3 (11.5) | 0 |
| Palmar-plantar erythrodysesthesia | 3 (11.5) | 0 |
| Nail disorder | 2 (7.7) | 1 (3.8) |
| Constipation | 2 (7.7) | 0 |
| Dermatitis acneiform | 2 (7.7) | 0 |
| Dry eye | 2 (7.7) | 0 |
| Mucosal inflammation | 2 (7.7) | 0 |
aNo grade 4 or 5 treatment-related toxicities were reported.